Pharmacokinetics of VP16-213 in Lewis lung carcinoma bearing mice
- 1 April 1982
- journal article
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 7 (2-3) , 127-131
- https://doi.org/10.1007/bf00254534
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- High-performance liquid chromatography determination of 4′-demethyl-epipodophyllotoxin-9-(4,6-O-ethylidene β-d-glucopyranoside) (VP 16-213) in human plasmaJournal of Chromatography B: Biomedical Sciences and Applications, 1981
- Etoposide (VP-16-213)Cancer Treatment Reviews, 1979
- VM 26 and VP 16–213: A comparative analysisCancer, 1977
- DIFFERENTIAL DISTRIBUTION OF ANTI-TUMOR AGENTS IN PRIMARY AND SECONDARY TUMORS1977
- Antimetastasis effect of two derivatives of epipodophyllotoxin in micePublished by Elsevier ,1976
- Comparison of the human pharmacokinetics of VM-26 and VP-16, two antineoplastic epipodophyllotoxin glucopyranoside derivativesPublished by Elsevier ,1975
- 4'-demethylepipodophyllotoxin 9-(4,6-o-2-thenylidene-beta-D-glucopyranoside) (NSC-122819; VM-26) and 4'-demethylepipodophyllotoxin 9-(4.6-0-ethylidene-beta-D-glucopyranoside) (NSC-141540; VP-16-213) in childhood cancer: preliminary observations.1975
- Activity of a new glycosidic lignan derivative (VP 16-213) related to podophyllotoxin in experimental tumorsPublished by Elsevier ,1973
- Phase I clinical trial of a new antitumor agent, 4'-demethylepipodophyllotoxin 9-(4,6-O-ethylidene- -D-glucopyranoside) (NSC-141540; VP-16-213).1972